What is the difference between Contrave and Wegovy?

They are different drugs that work in different ways. Contrave is an oral pill taken twice daily that combines naltrexone and bupropion to act on the brain's appetite and food-reward circuits. Wegovy is semaglutide, a once-weekly GLP-1 injection that slows gastric emptying and reduces appetite through gut-hormone signaling.

Which is more effective for weight loss, Contrave or Wegovy?

Wegovy is clearly more effective. In its STEP 1 trial, Wegovy produced about 14.9% weight loss versus 2.4% on placebo, while Contrave produced about 6.1% versus 1.3% on placebo in its COR-I trial. That is roughly 2.5 times more weight loss with Wegovy — a clinically major difference, not a rounding error.

Is Contrave better covered by insurance than Wegovy?

It sometimes is. Contrave is an oral option that can be covered when a GLP-1 like Wegovy is not, so coverage barriers are one reason people choose it. For someone whose insurance excludes GLP-1s, Contrave's roughly 6% weight loss is still a real, meaningful result, even though Wegovy is the more effective drug.

Why would someone choose Contrave over Wegovy?

Contrave loses the effectiveness contest but still fits some people. It is oral, so there are no injections; it specifically targets food reward and cravings, which can suit emotional or reward-driven eating; the bupropion component may help mood; and it is sometimes covered when a GLP-1 is not. For those who cannot or will not inject, it remains a reasonable choice.

← Research

GLP-1

Contrave vs Wegovy: the weight-loss gap is large

Both are approved weight-loss drugs, but Wegovy (a GLP-1 injection) produced ~14.9% weight loss versus ~6.1% for the oral Contrave — about 2.5 times more. Contrave's niche is being needle-free.

Julian RothJune 4, 20266 min read

Contrave versus Wegovy is a real choice between two approved weight-loss medications — not the same molecule in different packaging, but genuinely different drugs that work in different ways and produce very different results. The honest comparison comes down to effectiveness versus form.

Two different mechanisms

Contrave combines two old drugs: naltrexone (an opioid-receptor blocker) and bupropion (an antidepressant). Together they act on the brain’s appetite and food-rewardcircuits, taken as a pill twice daily. Wegovy is semaglutide, a GLP-1 receptor agonist — a once-weekly injection that slows gastric emptying and powerfully reduces appetite through gut-hormone signaling. Different targets, very different potency.

The weight-loss gap

The effectiveness difference is large. In its pivotal COR-I trial, Contrave (at the approved dose) produced about 6.1% weight loss versus 1.3% on placebo.^[1] Wegovy, in the STEP 1 trial, produced about 14.9% weight loss versus 2.4% on placebo.^[2]That’s roughly 2.5 times more weight loss with Wegovy — a clinically major difference, not a rounding error.

Wegovy (semaglutide 2.4 mg)14.9%
Contrave (naltrexone-bupropion)6.1%

Mean weight loss in each drug's pivotal trial — Wegovy (STEP 1) versus Contrave (COR-I). Units: % body weight. STEP 1 (PMID 33567185); COR-I (PMID 20673995)

Wegovy wins decisively on weight loss; Contrave's advantages are being oral and targeting reward-driven eating.
	Wegovy (semaglutide)	Contrave (naltrexone-bupropion)
Type	GLP-1 injection	Oral combination pill
Mechanism	Gut-hormone appetite signaling	Appetite + food-reward circuits
Dosing	Once weekly	Twice daily
Weight loss (trial)	~14.9%	~6.1%
Needle-free?	No	Yes

Wegovy wins decisively on weight loss; Contrave's advantages are being oral and targeting reward-driven eating. STEP 1 (PMID 33567185); COR-I (PMID 20673995)

The honest verdict

For maximum weight loss, this isn’t close: Wegovy produced roughly 2.5 times the weight loss of Contrave in their respective trials.^[1]^[2] If effectiveness is the priority and a weekly injection is acceptable, Wegovy is the stronger choice. Contrave is the reasonable pick for people who need an oral option, have reward-driven eating, or face GLP-1 coverage barriers. To compare Wegovy against the tirzepatide brand, see Zepbound vs Wegovy; for the older injectable, Wegovy vs Saxenda; and for cost and access, our Wegovy cost guide and provider comparison.

Reviewed against primary sources by the Aminoscope desk

Frequently asked

What is the difference between Contrave and Wegovy?: They are different drugs that work in different ways. Contrave is an oral pill taken twice daily that combines naltrexone and bupropion to act on the brain's appetite and food-reward circuits. Wegovy is semaglutide, a once-weekly GLP-1 injection that slows gastric emptying and reduces appetite through gut-hormone signaling.
Which is more effective for weight loss, Contrave or Wegovy?: Wegovy is clearly more effective. In its STEP 1 trial, Wegovy produced about 14.9% weight loss versus 2.4% on placebo, while Contrave produced about 6.1% versus 1.3% on placebo in its COR-I trial. That is roughly 2.5 times more weight loss with Wegovy — a clinically major difference, not a rounding error.
Is Contrave better covered by insurance than Wegovy?: It sometimes is. Contrave is an oral option that can be covered when a GLP-1 like Wegovy is not, so coverage barriers are one reason people choose it. For someone whose insurance excludes GLP-1s, Contrave's roughly 6% weight loss is still a real, meaningful result, even though Wegovy is the more effective drug.
Why would someone choose Contrave over Wegovy?: Contrave loses the effectiveness contest but still fits some people. It is oral, so there are no injections; it specifically targets food reward and cravings, which can suit emotional or reward-driven eating; the bupropion component may help mood; and it is sometimes covered when a GLP-1 is not. For those who cannot or will not inject, it remains a reasonable choice.

Sources

[1] Greenway FL, Fujioka K, Plodkowski RA, et al. (2010). Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. PMID 20673995
[2] Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. PMID 33567185

Related tool

GLP-1 weight-loss comparison

See semaglutide, tirzepatide, retatrutide and the pipeline ranked by mean trial weight loss — every figure traced to its source.